Britain and America have agreed to a important bilateral deal that will maintain zero import taxes on UK drug shipments entering the US market.
The Terms of the Accord
As part of the deal, the UK has pledged to boost expenditure on medicines through the NHS. This pledge ensures that import taxes on these key exports will stay at zero for a timeframe of 36 months.
This development follows earlier threats to hike tariffs on patented drug imports, with potential rates mentioned as high as 100%.
"This arrangement with the United Kingdom strengthens the global environment for new treatments and introduces much-needed balance to U.S.–U.K. medicine commerce," an announcement noted.
Commercial Significance
Medicines constitute one of the Britain's largest goods shipped to the America, which is easily the largest destination for large British pharmaceutical firms.
Export figures reveal that in the one-year period to the end of September, the UK shipped medicines totaling billions to the US. This amount made up nearly one-fifth of total UK exports in that span.
"This deal safeguards work, increases capital expenditure and sets the stage for the UK to emerge as a international leader for life sciences," a minister remarked.
Specific British Pledges
The pact includes several notable changes from the British government:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it deems new therapies to be prohibitively costly by twenty-five percent.
- Increased NHS Spending: There is a aim to increase overall health service expenditure on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Refund Ceiling: The percentage drug companies must pay back to the NHS to prevent overspending will be restricted at fifteen percent. Last year, refunds were more than 20%.
Broader Context
The deal takes place against a long-running row between the pharmaceutical industry and the British authorities over drug pricing and NHS adoption.
This friction were intensified by arguments that American customers were charged significantly more for the same drugs than patients in the UK and Europe.
Over the last 18 months, several major drug company projects in the UK have been delayed or abandoned, while major investments have been pledged toward projects in the United States.
One official acknowledged that the NHS had to spend more on medicines, noting that its expenditure on drugs had decreased as a proportion of its resources over the last ten years.
